非酒精性脂肪性肝病与肠道微生态

doi:10.3969/j.issn.1672-5069.2023.03.002

Abstract

Qiu Liying, Wang Yingchun. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives[J]. Journal of Practical Hepatology, 2023, 26(3): 308-312.

References

[1] 非酒精性脂肪性肝病防治指南(2018年更新版) . 实用肝脏病杂志, 2018, 21(2): 177-186.
[2] Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol, 2017, 23(36): 6571-6592.
[3] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature. Int J Mol Sci, 2019, 20(2):213-216.
[4] 屈爱娜, 吴德. 人体肠道病毒群的宏基因组学研究进展. 病毒学报, 2022, 38(6): 1488-1494.
[5] 唐圆, 贺璐, 谢果珍, 等. 肠道真菌研究进展. 中国微生态学杂志, 2019, 31(11): 1341-1346.
[6] 王玉栎, 刘畅, 牛辰, 等. IM影响非酒精性脂肪性肝病的机制及应对策略. 微生物与感染, 2021, 16(5): 347-355.
[7] Jadhav K, Cohen T S. Can Yyou trust your gut? Implicating a disrupted intestinal microbiome in the progression of NAFLD/NASH. Front Endocrinol (Lausanne), 2020, 11: 592157.
[8] 李宝龙, 王娇娇, 段婷婷, 等. 基于IM调节的中医药防治非酒精性脂肪肝的研究进展. 医学综述, 2019, 25(21): 4281-4285.
[9] Lu Q, Stappenbeck T S. Local barriers configure systemic communications between the host and microbiota. Science, 2022, 376(6596): 950-955.
[10] Mu J, Tan F, Zhou X, et al. Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. Food Funct, 2020, 11(10): 8707-8023.
[11] Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol, 2020, 72(3): 558-577.
[12] 周张宁, 张勤, 归崎峰, 等. 肠道微生态与肌少症研究新进展. 中华老年医学杂志, 2022, 41(5): 610-613.
[13] Zhou D, Fan J G. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol, 2019, 25(17): 2019-2028.
[14] 中国微生态调节剂临床应用专家共识(2020版) . 中华临床感染病杂志, 2020, 13(4): 241-256.
[15] 陈玉冰, 郭振亚, 袁观斗, 等. 非酒精性脂肪性肝病与IM紊乱关系的研究进展. 中华实验外科杂志, 2019, 34(7): 1334-1337.
[16] Radziejewska A, Muzsik A, Milagro F I, et al. One-carbon metabolism and nonalcoholic fatty liver disease: The crosstalk between nutrients, microbiota, and genetics. Lifestyle Genom, 2020, 13(2): 53-63.
[17] Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: A new insight into therapeutic strategies. Nutrients, 2019, 11(11):612-617.
[18] Yao F, Jia R, Huang H, et al. Effect of lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Arch Med Sci, 2019, 15(5): 1336-1344.
[19] Yu Y, Liu Y, An W, et al. STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Invest, 2019, 129(2): 546-555.
[20] Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: Current evidence and perspectives. Biomolecules, 2021, 12(1):1-5.
[21] Ortiz-Alvarez L, Xu H, Martinez-Tellez B. Influence of exercise on the human gut microbiota of healthy adults: A systematic review. Clin Transl Gastroenterol, 2020, 11(2): e00126.
[22] Lanthier N, Delzenne N. Targeting the gut microbiome to treat metabolic dysfunction-associated fatty liver disease: Ready for prime time? Cells, 2022, 11(17):419-421.
[23] Suk K T, Kim D J. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2019, 13(3): 193-204.
[24] Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr, 2017, 117(5): 662-668.
[25] Vallianou N, Stratigou T, Christodoulatos G S, et al. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: Current evidence, controversies, and perspectives. Curr Obes Rep, 2020, 9(3): 179-192.
[26] Vinderola G, Sanders M E, Salminen S, et al. Postbiotics: The concept and their use in healthy populations . Front Nutr, 2022, 9: 1002213.
[27] Lechner S, Yee M, Limketkai B N, et al. Fecal microbiota transplantation for chronic liver diseases: Current understanding and future direction. Dig Dis Sci, 2020, 65(3): 897-905.
[28] Feuerstadt P, Louie T J, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med, 2022, 386(3): 220-229.
[29] Suk K T, Koh H. New perspective on fecal microbiota transplantation in liver diseases . J Gastroenterol Hepatol, 2022, 37(1): 24-33.
[30] Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial. Front Cell Infect Microbiol, 2022, 12: 759306.
[31] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep, 2017, 7(1): 1529.
[32] Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am J Gastroenterol, 2020, 115(7): 1055-1065.
[33] Lu J, Jin X, Yang S, et al. Immune mechanism of gut microbiota and its metabolites in the occurrence and development of cardiovascular diseases. Front Microbiol, 2022, 13: 1034537.
[34] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575(7783): 505-511.
[35] 孙艺凡, 张霞, 王晓艳, 等. 长期服用人参提取物对大鼠IM结构的影响. 中国中药杂志, 2018, 43(19): 3927-3932.

Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhan Qirui, Duan Taimei, Yan Jie. Changes of serum amyloid A, plasma heme oxygenase-1 and bone morphogenetic protein 9 levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 348-351.
[2]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[3]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[4]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[5]	Chen Fenglian, Zhu Qinglan, Zhu Lingli, et al. Different activation of peripheral blood invariant natural killer T cells and CD4⁺/CD8⁺T cells in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(1): 31-34.
[6]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[7]	Liu Yantong, Yao Yang, Lu Bo. Short-term efficacy of Heye Tiaozhi Shugan Decoction in dealing with patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 657-660.
[8]	CheDepartment of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai , Chinan Mengqi, Fan Jiangao. Brief introduction of a clinical practice guideline for the diagnosis and management of patients with nonalcoholic fatty liver diseases in USA [J]. Journal of Practical Hepatology, 2022, 25(5): 0-S16.
[9]	Wang Qing, Zhang Lili. When T2DM comes across with NAFLD:1+1＞2？ [J]. Journal of Practical Hepatology, 2022, 25(4): 460-463.
[10]	Cai Dongmei, Wu Wenjuan, Jiang Yilun, et al. Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque [J]. Journal of Practical Hepatology, 2022, 25(3): 383-386.
[11]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[12]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[13]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[14]	Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease [J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.
[15]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.